TIVUS II Study

  • Research type

    Research Study

  • Full title

    Clinical evaluation of the Therapeutic Intra-Vascular Ultrasound (TIVUS™) System for renal denervation in patients with resistant hypertension

  • IRAS ID

    136725

  • Contact name

    Melvin Lobo

  • Contact email

    m.d.lobo@qmul.ac.uk

  • Sponsor organisation

    Cardiosonic, Ltd.

  • Clinicaltrials.gov Identifier

    NCT01835535

  • Research summary

    The TIVUS II Study is a worldwide, long term clinical study of the safety and performance of renal denervation (reduction of renal nerves activity) technology performed by the Therapeutic Intra Vascular Ultrasounds ( TIVUS™) System. Patients with resistance HTN, whose blood pressure remains high despite administrating over three anti-HTN drugs including diuretics are at higher risk of heart attack, stroke, heart failure, kidney disease and death. Aggressive treatment with lifestyle changes and drugs may not control their problem.
    This study continues the evaluation of the TIVUS™ System on humans. This new treatment is based on a relatively new, but proven, technique called “renal denervation”. This treatment uses a short procedure to deliberately heating and affecting the nerves activity surrounding the renal arteries (renal denervation), using ultrasound technology. As a result of a reduction in the nerves activity, the blood pressure is reduced. This has been adapted by NICE as an optional treatment for uncontrolled patients.
    The study will include up to 80 patients in Australia, Europe and Israel. They will be sub-divided to 3 cohorts, differing at their blood pressure inclusion values (>160mmHg, >140mmHg and >150mmHg with failed previous radio frequency (RF) denervation therapy). Patients found eligible will be treated. Under local anesthesia, a long catheter (hollow tube) is inserted into a blood vessel in the patient’s groin, and directed to the renal arteries. This is performed while imaging the renal arteries, using X ray. This technology uses ultrasound aimed to affect the nerves and their surrounding tissue. As opposed to currently used renal denervation technique, RF, the ultrasound doesn’t required contact with the artery wall, which may imply safer procedure, less pain and more effective.

  • REC name

    East of England - Cambridge East Research Ethics Committee

  • REC reference

    13/EE/0297

  • Date of REC Opinion

    4 Nov 2013

  • REC opinion

    Further Information Favourable Opinion